Anar al contingut
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • Dupilumab efficacy in uncontro...
  • Citar
  • Enviar aquest missatge de text
  • Enviar per correu electrònic aquest
  • Imprimir
  • Exportar registre
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Enllaç permanent
Dupilumab efficacy in uncontrolled, moderate-to-serve allergic asthma in the phase 3 liberty asthma quest study

Dupilumab efficacy in uncontrolled, moderate-to-serve allergic asthma in the phase 3 liberty asthma quest study

Dades bibliogràfiques
Autors principals: Castro, M, Corren, J, Hanania, N, Pavord, I, Quirce, S, Thangavelu, K, Rice, M, O'Riordan, T, Maroni, J, Rowe, P, Lu, Y, Amin, N, Ruddy, M, Akinlade, B, Graham, N, Teper, A
Format: Conference item
Publicat: Elsevier 2018
  • Fons
  • Descripció
  • Ítems similars
  • Visualització del personal

Ítems similars

  • Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the Liberty Asthma Quest study
    per: Maspero, J, et al.
    Publicat: (2018)
  • A randomized, controlled phase 3 study, Liberty Asthma Quest, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma
    per: Castro, M, et al.
    Publicat: (2018)
  • Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study
    per: Pavord, I, et al.
    Publicat: (2018)
  • Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST
    per: Wenzel, SE, et al.
    Publicat: (2018)
  • Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
    per: Mario Castro, et al.
    Publicat: (2020-01-01)

Opcions de cerca

  • Historial de cerca
  • Cerca avançada

Trobar-ne més

  • Explorar el catàleg
  • Explorar alfabèticament
  • Explora canals
  • Bibliografia recomanada
  • Nous ítems

Necessites ajuda?

  • Consells de cerca
  • Pregunteu al bibliotecari
  • FAQs